Jefferies analysts forecast a $1 billion market opportunity for each of Sarepta’s siRNA programs for facioscapulohumeral ...

Novartis has significantly strengthened its neuroscience pipeline over recent years, topped by the $12bn acquisition of ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided updates on the Company's clinical programs and highlighted major milestones for 2026.

Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to ...

He Jiankui spent three years in prison after creating gene-edited babies. Now back at work, he sees a greater opening for ...

The US bio company Dyne Therapeutics, which develops treatment substances for rare neuromuscular diseases such as Duchenne ...

The Muscular Dystrophy Association has opened applications for its 2026 college scholarship program for students with ...

The former CEO of The Painted Turtle, a nonprofit camp for children with serious medical conditions, has been charged with ...

Axial myopathy is a general term for a group of myopathies affecting the axial muscles. Axial myopathy appears to be a grossly underestimated feature of many muscle diseases and often overlooked ...

These days, college football recruiting is more about the money the athletes can now make in what has become a semi-pro ...

Learn more about whether Perrigo Company plc or Wave Life Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued stocks in the Biotechnology industry for Tuesday, January 13, 2026. Let’s ...